NAD Injections: How They Work and What Providers Should Know

The delivery method question comes up constantly in longevity programs – patients arrive having already researched NAD supplements, read about IV infusions, maybe seen something about patches or nasal sprays, and they want to know why their provider is recommending injections specifically. It’s a fair question. The injectable route bypasses first-pass gastrointestinal metabolism — a pharmacokinetic property of subcutaneous and intramuscular delivery methods that some providers factor into protocol design when NAD+ availability is a priority. For providers designing protocols where consistent NAD+ availability is a priority, that pharmacokinetic distinction is one factor in the delivery method conversation — alongside patient schedule, tolerance for in-office time, and clinical goals.

At MediVera, we compound and dispense NAD formulations for providers running these programs across the country. The questions below reflect what those providers – and their patients – actually ask.

What Is an NAD Injection?

NAD – nicotinamide adenine dinucleotide – is a coenzyme that lives in every cell in the body. It’s not a supplement in the conventional sense. It’s more like a required operating input for core biochemical processes — the kind that have made NAD+ a subject of active scientific investigation in longevity and metabolic research. The coenzyme cycles between two states (NAD+ and NADH) as it shuttles electrons through metabolic reactions, which is why NAD+ levels matter broadly rather than in any single tissue.

The clinical question of whether and how to address NAD+ levels is one a licensed provider evaluates individually.

A compounded NAD injection — a formulation of NAD+ or an NAD precursor prepared for subcutaneous or intramuscular delivery — is one tool a prescribing provider may consider as part of a broader individualized protocol. The injection route skips first-pass gastrointestinal metabolism entirely. For prescribers factoring pharmacokinetics into protocol design, the difference in how each delivery method reaches systemic circulation is one element worth discussing with patients alongside convenience, cost, and cadence.

What the Research Says About NAD+ as a Coenzyme Class

The published literature on NAD+ and its precursors has grown substantially, and it’s worth being specific about what that literature actually shows. Compounded NAD injections are not FDA-approved treatments for any disease or condition. The mechanisms below are attributed to NAD+ as a coenzyme class – not to any specific compounded formulation – and the research spans a spectrum from well-replicated animal data to early-stage human trials with smaller sample sizes.

Areas of active scientific investigation include:

• Cellular energy metabolism. NAD+ is a required co-substrate for the enzymes driving ATP production in mitochondria. Without adequate NAD+, that production process slows – this is the most mechanistically grounded part of the research base, and the reason cellular energy comes up consistently in longevity discussions.
• Sirtuin pathway function. Sirtuins regulate cellular responses to energy status and oxidative stress, and can’t function without NAD+ as a co-substrate. The relationship between NAD+ availability and sirtuin activity has been examined in both animal models and early human studies — though what that means clinically for aging remains an open question.
• DNA repair capacity. PARP enzymes detect and respond to DNA strand breaks, consuming NAD+ in the process. Adequate NAD+ availability is thought to support the cell’s ability to run that repair machinery – which is why this area draws attention in longevity research even though human evidence is still developing.
• Circadian clock regulation. There’s an emerging line of research connecting NAD+ availability to circadian rhythm function, with downstream implications for sleep quality and metabolic timing. It’s a newer area and the human data is limited, but it tracks mechanistically.
• Brain energy metabolism. Preclinical work has looked at NAD+ precursors in relation to neuroprotective pathways and brain energy availability. Human evidence is limited so far, but the animal data is enough that most serious longevity researchers consider it worth watching.
• Metabolic markers in aging populations. Some early human trials have examined NAD+ precursor supplementation alongside insulin sensitivity and other metabolic markers. The sample sizes are small, the results are mixed, and this is probably the area where the research is furthest from clinical conclusions.

Providers who incorporate NAD injections into longevity protocols typically frame them as support for cellular function – not as treatment for a diagnosed condition. The prescription model is what makes individualized compounding the right pathway here. One patient’s protocol may look very different from another’s based on where their baseline labs sit, what else they’re taking, and what the prescriber is trying to accomplish.

NAD Plus Injections vs. Other Delivery Methods

There’s no single right answer on delivery method – the choice depends on what a provider is trying to accomplish for a particular patient, and what that patient’s schedule and tolerance for in-office time actually look like.

The injectable route occupies a practical middle position for telehealth-based programs, offering home self-administration with consistent delivery and a dosing cadence a provider can design around. IV infusions can deliver very high NAD+ concentrations quickly, but they require the patient to sit in a clinical setting for two to four hours per session – which works for some patients and not at all for others. Oral NR and NMN have real research behind them and are appropriate for plenty of patients, especially on maintenance.

Providers prescribing NAD injections through MediVera can have formulations shipped directly to patients, with most compounds leaving our facility within 48 hours. That turnaround matters in longevity programs where protocol consistency is part of the clinical rationale.

NAD Injections Before and After: What to Expect During a Protocol

Patients asking about NAD injections “before and after” are usually asking two separate things at once – what the injection process actually involves, and what changes they might notice over time. Those deserve separate answers.

The Injection Experience

Compounded NAD injections are most commonly prescribed for subcutaneous administration – the same route used for insulin and most peptide protocols. Patients typically inject into the abdomen or outer thigh. The process is brief. Some patients report mild, transient discomfort at the injection site, which is typical of subcutaneous formulations and generally not a reason to stop.

Providers who work with MediVera have access to patient education support – patient education resources covering administration technique and protocol expectations. If questions come up during a protocol, our team is reachable; we answer most calls within 30 seconds and follow up with patients within one business day.

Protocol Duration and Cadence

NAD injection protocols don’t follow a single template. The prescribing provider sets the structure based on what the patient needs and how they want to sequence the intervention. In practice, providers typically start patients at a low dose. From there, the provider may titrate upward if they determine it’s appropriate, or the patient may remain at a lower dose for the duration of the protocol. There is no universal target dose, and there’s no requirement to escalate. Those decisions belong to the prescribing provider, who determines dosing and cadence based on the individual patient’s labs, goals, and other compounds in use. MediVera dispenses exactly what the prescription specifies.

MediVera compounds and dispenses based on the individualized prescription written for each patient. That’s not a formality. It’s the defining characteristic of 503A compounding pharmacy practice, and it’s why no two patients’ protocols look identical even when they’re using the same compounds.

Patient Experiences May Vary

Individual physiology, baseline status, and other compounds in use all influence how a protocol unfolds — factors a prescribing provider is better positioned to evaluate than any pharmacy. MediVera does not characterize expected outcomes; those conversations belong between patient and provider. What we can speak to: our team follows up with patients within one business day of prescription receipt, and our pharmacists are reachable by phone throughout the protocol.

NAD Injections Near Me: Telehealth Access Through a Licensed Compounding Partner

Searching “NAD injections near me” is an understandable reflex – you want a pharmacy that has accountability, not just a website. The geographic reality of specialized compounding is that the highest-quality option for your provider’s program is rarely the one closest to your zip code. For most patients, that stopped being a logistical problem when telehealth prescribing became mainstream.

Patients nationwide can work with a telehealth provider licensed in their state, receive a prescription for compounded NAD injections, and have those formulations shipped directly to their door from a PCAB-accredited pharmacy – no clinic visit required. The pharmacy handling the compound doesn’t need to be local. It needs to be licensed in your state, operating under documented quality standards, and able to ship reliably.

MediVera is licensed in 49 states, with expansion ongoing. Our longevity compounding services support providers across telehealth platforms and private practices running NAD-based programs. The better question – for patients and providers both – isn’t which pharmacy is geographically nearest. It’s which pharmacy has the accreditation, the testing investment, and the fulfillment infrastructure to actually support the protocol without the variables that create problems mid-program.

For providers evaluating compounding partners, the criteria that matter are state licensing coverage, accreditation status, third-party testing documentation, and the ability to communicate clearly with patients when questions arise. Those are what MediVera is built around.

How MediVera Compounds NAD Injections: Quality and Compliance Standards

Compounded medications aren’t FDA-approved – that’s a fact, not a caveat. It doesn’t mean they’re unregulated. It means the regulatory framework is different: state pharmacy boards, federal compounding law, and voluntary accreditation programs that go well beyond what state licensure requires on its own. Most compounding pharmacies operate at the state licensure level. PCAB dual accreditation — covering both sterile and non-sterile compounding — is a different category. Fewer than 1% of compounding pharmacies hold both credentials.

MediVera holds PCAB accreditation in both sterile and non-sterile compounding – the dual credential. The American Medical Association recommends PCAB-accredited pharmacies specifically, which is one of the few cases where a major medical organization has taken a position on which compounding partners providers should use. Our quality and compliance standards are documented in detail, but the numbers that are most relevant to NAD injection protocols look like this:

• $60,000+ monthly in third-party potency and sterility testing – that’s independent verification, not internal QA alone
• ISO-7 cleanrooms and ISO-5 hoods for all sterile compounding operations
• USP 795, 797, and 800 compliance covering non-sterile, sterile, and hazardous drug categories
• Ingredients from FDA-registered suppliers exclusively – the sourcing end of the quality chain matters as much as compounding conditions
• Nine licensed compounding pharmacists on staff across formulation and QA functions

NAD injections fall under USP 797 – the sterile compounding standard. That framework requires controlled cleanroom environments, validated beyond-use dating, endotoxin testing, and sterility verification on finished lots. I’d call those details incidental, but they’re not. A formulation compounded outside those conditions can fail to perform or, worse, introduce contamination risk. The standard exists for a reason.

Providers partnering with MediVera get dedicated account management, clinical education support, and a shipping operation that gets most compounds to patients within 48 hours. For practices running high-volume longevity programs, that reliability matters as much as the quality of the compounds themselves – because a good formulation that arrives inconsistently is still a problem.

Patients interested in NAD injection protocols need to work with a licensed healthcare provider who can evaluate whether the approach fits their individual situation. MediVera dispenses compounded NAD formulations by prescription only, as individualized preparations for specific patients. Compounded NAD injections are not FDA-approved and are not intended as replacements for FDA-approved therapies.

Providers ready to discuss NAD injection programs, or patients with questions about how the compounding process works, can visit Longevity Compounding Medicine or contact our team directly.